Does 30-day readmission affect long-term outcome among glioblastoma patients?

Miriam Nuño, Diana Ly, Alicia Ortega, J. Manuel Sarmiento, Debraj Mukherjee, Keith L. Black, Chirag G. Patil

Research output: Contribution to journalArticle

Abstract

Background: Research on readmissions has focused mainly on the economic and resource burden it places on hospitals. Objective: To evaluate the effect of 30-day readmission on overall survival among newly diagnosed glioblastoma multiforme (GBM) patients. Methods: A nationwide cohort of GBM patients diagnosed between 1991 and 2007 was studied using the Surveillance, Epidemiology and End Results Medicare database. Multivariate models were used to determine factors associated with readmission and overall survival. Odds ratio, hazard ratio, 95% confidence interval, and P values were reported. Complete case and multiple imputation analyses were performed. Results: Among the 2774 newly diagnosed GBM patients undergoing surgery at 442 hospitals nationwide, 437 (15.8%) were readmitted within 30 days of the index hospitalization. Although 63% of readmitted patients returned to the index hospital where surgery was performed, a significant portion (37%) were readmitted to nonindex hospitals. The median overall survival for readmitted patients (6.0 months) was significantly shorter than for nonreadmitted (7.6 months; P <.001). In a confounder-adjusted imputed model, 30-day readmission increased the hazard of mortality by 30% (hazard ratio, 1.3; P <.001). Neurological symptoms (30.2%), thromboembolic complications (19.7%), and infections (17.6%) were the leading reasons for readmission. Conclusion: Prior studies that have reported only the readmissions back to index hospitals are likely underestimating the true 30-day readmission rate. GBM patients who were readmitted within 30 days had significantly shorter survival than nonreadmitted patients. Future studies that attempt to decrease readmissions and evaluate the impact of reducing readmissions on patient outcomes are needed.

Original languageEnglish (US)
Pages (from-to)196-204
Number of pages9
JournalNeurosurgery
Volume74
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Glioblastoma
Survival
Patient Readmission
Medicare
Epidemiology
Hospitalization
Odds Ratio
Economics
Databases
Confidence Intervals
Mortality
Infection
Research

Keywords

  • 30-Day readmission
  • Glioblastoma multiforme
  • Overall survival

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Nuño, M., Ly, D., Ortega, A., Sarmiento, J. M., Mukherjee, D., Black, K. L., & Patil, C. G. (2014). Does 30-day readmission affect long-term outcome among glioblastoma patients? Neurosurgery, 74(2), 196-204. https://doi.org/10.1227/NEU.0000000000000243

Does 30-day readmission affect long-term outcome among glioblastoma patients? / Nuño, Miriam; Ly, Diana; Ortega, Alicia; Sarmiento, J. Manuel; Mukherjee, Debraj; Black, Keith L.; Patil, Chirag G.

In: Neurosurgery, Vol. 74, No. 2, 01.01.2014, p. 196-204.

Research output: Contribution to journalArticle

Nuño, M, Ly, D, Ortega, A, Sarmiento, JM, Mukherjee, D, Black, KL & Patil, CG 2014, 'Does 30-day readmission affect long-term outcome among glioblastoma patients?', Neurosurgery, vol. 74, no. 2, pp. 196-204. https://doi.org/10.1227/NEU.0000000000000243
Nuño, Miriam ; Ly, Diana ; Ortega, Alicia ; Sarmiento, J. Manuel ; Mukherjee, Debraj ; Black, Keith L. ; Patil, Chirag G. / Does 30-day readmission affect long-term outcome among glioblastoma patients?. In: Neurosurgery. 2014 ; Vol. 74, No. 2. pp. 196-204.
@article{be9fcec7e39745f5b2ec9db29ecf9d9f,
title = "Does 30-day readmission affect long-term outcome among glioblastoma patients?",
abstract = "Background: Research on readmissions has focused mainly on the economic and resource burden it places on hospitals. Objective: To evaluate the effect of 30-day readmission on overall survival among newly diagnosed glioblastoma multiforme (GBM) patients. Methods: A nationwide cohort of GBM patients diagnosed between 1991 and 2007 was studied using the Surveillance, Epidemiology and End Results Medicare database. Multivariate models were used to determine factors associated with readmission and overall survival. Odds ratio, hazard ratio, 95{\%} confidence interval, and P values were reported. Complete case and multiple imputation analyses were performed. Results: Among the 2774 newly diagnosed GBM patients undergoing surgery at 442 hospitals nationwide, 437 (15.8{\%}) were readmitted within 30 days of the index hospitalization. Although 63{\%} of readmitted patients returned to the index hospital where surgery was performed, a significant portion (37{\%}) were readmitted to nonindex hospitals. The median overall survival for readmitted patients (6.0 months) was significantly shorter than for nonreadmitted (7.6 months; P <.001). In a confounder-adjusted imputed model, 30-day readmission increased the hazard of mortality by 30{\%} (hazard ratio, 1.3; P <.001). Neurological symptoms (30.2{\%}), thromboembolic complications (19.7{\%}), and infections (17.6{\%}) were the leading reasons for readmission. Conclusion: Prior studies that have reported only the readmissions back to index hospitals are likely underestimating the true 30-day readmission rate. GBM patients who were readmitted within 30 days had significantly shorter survival than nonreadmitted patients. Future studies that attempt to decrease readmissions and evaluate the impact of reducing readmissions on patient outcomes are needed.",
keywords = "30-Day readmission, Glioblastoma multiforme, Overall survival",
author = "Miriam Nu{\~n}o and Diana Ly and Alicia Ortega and Sarmiento, {J. Manuel} and Debraj Mukherjee and Black, {Keith L.} and Patil, {Chirag G.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1227/NEU.0000000000000243",
language = "English (US)",
volume = "74",
pages = "196--204",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Does 30-day readmission affect long-term outcome among glioblastoma patients?

AU - Nuño, Miriam

AU - Ly, Diana

AU - Ortega, Alicia

AU - Sarmiento, J. Manuel

AU - Mukherjee, Debraj

AU - Black, Keith L.

AU - Patil, Chirag G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Research on readmissions has focused mainly on the economic and resource burden it places on hospitals. Objective: To evaluate the effect of 30-day readmission on overall survival among newly diagnosed glioblastoma multiforme (GBM) patients. Methods: A nationwide cohort of GBM patients diagnosed between 1991 and 2007 was studied using the Surveillance, Epidemiology and End Results Medicare database. Multivariate models were used to determine factors associated with readmission and overall survival. Odds ratio, hazard ratio, 95% confidence interval, and P values were reported. Complete case and multiple imputation analyses were performed. Results: Among the 2774 newly diagnosed GBM patients undergoing surgery at 442 hospitals nationwide, 437 (15.8%) were readmitted within 30 days of the index hospitalization. Although 63% of readmitted patients returned to the index hospital where surgery was performed, a significant portion (37%) were readmitted to nonindex hospitals. The median overall survival for readmitted patients (6.0 months) was significantly shorter than for nonreadmitted (7.6 months; P <.001). In a confounder-adjusted imputed model, 30-day readmission increased the hazard of mortality by 30% (hazard ratio, 1.3; P <.001). Neurological symptoms (30.2%), thromboembolic complications (19.7%), and infections (17.6%) were the leading reasons for readmission. Conclusion: Prior studies that have reported only the readmissions back to index hospitals are likely underestimating the true 30-day readmission rate. GBM patients who were readmitted within 30 days had significantly shorter survival than nonreadmitted patients. Future studies that attempt to decrease readmissions and evaluate the impact of reducing readmissions on patient outcomes are needed.

AB - Background: Research on readmissions has focused mainly on the economic and resource burden it places on hospitals. Objective: To evaluate the effect of 30-day readmission on overall survival among newly diagnosed glioblastoma multiforme (GBM) patients. Methods: A nationwide cohort of GBM patients diagnosed between 1991 and 2007 was studied using the Surveillance, Epidemiology and End Results Medicare database. Multivariate models were used to determine factors associated with readmission and overall survival. Odds ratio, hazard ratio, 95% confidence interval, and P values were reported. Complete case and multiple imputation analyses were performed. Results: Among the 2774 newly diagnosed GBM patients undergoing surgery at 442 hospitals nationwide, 437 (15.8%) were readmitted within 30 days of the index hospitalization. Although 63% of readmitted patients returned to the index hospital where surgery was performed, a significant portion (37%) were readmitted to nonindex hospitals. The median overall survival for readmitted patients (6.0 months) was significantly shorter than for nonreadmitted (7.6 months; P <.001). In a confounder-adjusted imputed model, 30-day readmission increased the hazard of mortality by 30% (hazard ratio, 1.3; P <.001). Neurological symptoms (30.2%), thromboembolic complications (19.7%), and infections (17.6%) were the leading reasons for readmission. Conclusion: Prior studies that have reported only the readmissions back to index hospitals are likely underestimating the true 30-day readmission rate. GBM patients who were readmitted within 30 days had significantly shorter survival than nonreadmitted patients. Future studies that attempt to decrease readmissions and evaluate the impact of reducing readmissions on patient outcomes are needed.

KW - 30-Day readmission

KW - Glioblastoma multiforme

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=84893807299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893807299&partnerID=8YFLogxK

U2 - 10.1227/NEU.0000000000000243

DO - 10.1227/NEU.0000000000000243

M3 - Article

C2 - 24176955

AN - SCOPUS:84893807299

VL - 74

SP - 196

EP - 204

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 2

ER -